Nicole La Brosse Halozyme Therapeutics, Inc. (HALO) insider trading activity

Nicole La Brosse is SVP, CHIEF FINANCIAL OFFICER of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 28,813 shares of HALO, which is worth approximately $1.66 Million. The most recent transaction as insider was on Feb 16, 2025, when has been sold 15,011 shares (Common Stock) at a price of $58.29 per share, resulting in proceeds of $874,991. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 28.8K

86.13% 3M change

86.13% 12M change

Total Value Held $1.66 Million

Nicole LaBrosse Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 16 2025	SELL Payment of exercise price or tax liability	$874,991 $58.29 p/Share	15,011 Reduced 34.25%	28,813 Common Stock
Feb 16 2025	BUY Exercise of conversion of derivative security	-	27,831 Added 46.76%	31,682 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$43,192 $58.29 p/Share	741 Reduced 4.43%	15,993 Common Stock
Feb 15 2025	BUY Exercise of conversion of derivative security	-	1,254 Added 6.97%	16,734 Common Stock
Jul 22 2024	SELL Open market or private sale	$270,250 $54.05 p/Share	5,000 Reduced 24.41%	15,480 Common Stock
Jul 22 2024	BUY Exercise of conversion of derivative security	$112,500 $22.5 p/Share	5,000 Added 23.29%	16,472 Common Stock
Jun 28 2024	SELL Open market or private sale	$520,400 $52.04 p/Share	10,000 Reduced 39.25%	15,480 Common Stock
Jun 28 2024	BUY Exercise of conversion of derivative security	$225,000 $22.5 p/Share	10,000 Added 28.18%	25,480 Common Stock
Jun 27 2024	SELL Open market or private sale	$519,300 $51.93 p/Share	10,000 Reduced 39.25%	15,480 Common Stock
Jun 27 2024	BUY Exercise of conversion of derivative security	$225,000 $22.5 p/Share	10,000 Added 28.18%	25,480 Common Stock
Jun 26 2024	SELL Open market or private sale	$518,200 $51.82 p/Share	10,000 Reduced 39.25%	15,480 Common Stock
Jun 26 2024	BUY Exercise of conversion of derivative security	$225,000 $22.5 p/Share	10,000 Added 28.18%	25,480 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$202,196 $36.1 p/Share	5,601 Reduced 26.57%	15,480 Common Stock
Feb 16 2024	BUY Exercise of conversion of derivative security	-	10,422 Added 36.23%	18,344 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$24,634 $35.91 p/Share	686 Reduced 6.05%	10,659 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	-	1,254 Added 9.95%	11,345 Common Stock
Feb 10 2024	SELL Payment of exercise price or tax liability	$52,418 $35.49 p/Share	1,477 Reduced 12.77%	10,091 Common Stock
Feb 10 2024	BUY Exercise of conversion of derivative security	-	2,502 Added 17.78%	11,568 Common Stock
Feb 16 2023	SELL Open market or private sale	$124,381 $49.26 p/Share	2,525 Reduced 21.78%	9,066 Common Stock
Feb 16 2023	BUY Exercise of conversion of derivative security	-	5,094 Added 30.53%	11,591 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$30,553 $49.2 p/Share	621 Reduced 8.72%	6,497 Common Stock
Feb 15 2023	BUY Exercise of conversion of derivative security	-	1,254 Added 14.98%	7,118 Common Stock
Feb 12 2023	SELL Payment of exercise price or tax liability	$33,314 $48.92 p/Share	681 Reduced 10.4%	5,864 Common Stock
Feb 12 2023	BUY Exercise of conversion of derivative security	-	1,389 Added 17.51%	6,545 Common Stock
Feb 10 2023	SELL Payment of exercise price or tax liability	$68,096 $48.92 p/Share	1,392 Reduced 21.26%	5,156 Common Stock

Nicole La Brosse

SVP, CHIEF FINANCIAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account